

**Freedom of Information Act 2000****The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 06 July 2024****FOI Ref No: 25328****Requested Information:**

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatments at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Epcoritamab
- Loncastuximab tesirine
- Glofitamab
- Any other SACT
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatments

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

### Response:

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? **27**

Q1a. Of these patients, how many commenced treatments at your trust within the last 6 months? **24**

Q2. In the last 6 months (December 2023 to May 2024), RCHT treated the following numbers of patients for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) **12**
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) **7**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) **2**
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) **11**
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) **0**
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) **0**
- Axicabtagene ciloleucel (Yescarta) **0**
- Tisagenlecleucel **0**
- Epcoritamab **3**
- Loncastuximab tesirine **0**
- Glofitamab **2**
- Any other SACT:
  - Cytarabine + Methotrexate + Rituximab + Thiot **3**
  - R- EPOCH **1**
  - R-CE **3**
  - RCEOP **2**
  - R-GDP **1**
  - Rituximab **1**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta) **0**
- Tisagenlecleucel **0**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) **2**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatments

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

#### Additional Commentary

The response to the request for clinical trials for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) includes studies which are currently recruiting patients or have patients under treatment or in follow-up. It includes the numbers for participants who are currently undergoing treatment, in follow-up or under surveillance, excluding any patients who have not commenced treatment or who have completed treatment.

Study Short Title	Study Full Title	Active Participants (taking part or enrolling)
GCT3013-05 - A Phase 3 Trial of Epcoritamab vs SOC in R/R DLBCL	A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory DLBCL	1 on follow-up
REMoDL-A	A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib	7 on follow-up
Pola-R-ICE	An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)	2 on follow-up
EPCORE™ DLBCL-3	A randomized, open-label, multicenter, global, phase 2 trial to evaluate the efficacy and safety of epcoritamab (gen3013; duobody®-cd3xcd20) as monotherapy or in combination with lenalidomide as first-line therapy for anthracycline ineligible subjects with diffuse large b cell lymphoma	1 on treatment
ATHENA-1	A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)	0

**Attachment(s):**

None.

**Date Response sent: 05 August 2024**